ReviewFrontiers in pharmacology2026
Mannosylated nanocarriers: a precision targeting strategy for tumors and infectious diseases.
Review in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Targeting ARF6-SUCNR1 Axis: Antisense Oligonucleotide Adjuvants for Neutrophil Immunometabolism.International journal of molecular sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Conventional chemotherapy often suffers from systemic toxicity, suboptimal efficacy, and drug resistance due to the non-specific distribution of drugs in the treatment of tumors and infectious diseases. Mannose-functionalized nanodelivery systems present a promising precision-targeting strategy to overcome these challenges. The core of this strategy lies in leveraging the high expression of C-type mannose receptors (MR, CD206) on the surface of various tumor cells, tumor-associated macrophages (TAMs), and antigen-presenting cells (APCs). Not only do mannose-functionalized nanocarriers achieve precise drug delivery to specific cells via receptor-mediated endocytosis, but they also actively modulate the tumor immune microenvironment. This modulation occurs by activating antigen presentation mechanisms, thereby enhancing the host's immune response. Consequently, this system exhibits immense potential for intervention in both malignant tumors and infectious diseases. This review systematically summarizes nanodelivery platforms integrated with mannose-targeted strategies. Furthermore, it explores their recent advances and future application perspectives in combination with diverse therapeutic modalities, including chemotherapy, photodynamic therapy, and immunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.